OREANDA-NEWS. November 19, 2012. Group of companies “R-Pharm” acted as the official sponsor of Moscow International Forum for Innovative Development of “Open Innovations” that took place in Central Exhibition Complex “Expocentre” on October 3th - November 3rd. The Forum was arranged by leading Russian institutions for development (i.e. Skolkovo, Bank for Foreign Economic Activity, the Russian Corporation of Nanotechnologies (RUSNANO), Russian Ventures Company (RVC), the Fund for Assistance to Small Businesses in the scientific and technical area), the Agency of Strategic Initiatives (ASI), the Government of Moscow and the Chamber of Commerce and Industry of the Russian Federation. The Forum was dedicated to the latest technologies and the prospects of international cooperation in the innovations. Group of companies “R-Pharm” participated in a number of key sessions, held its own events, i.e. the Panel Discussion and the Business Breakfast Meeting dedicated to the innovations in health care practice, and organized the media events as well.

Alexey Repik, Chairman of the Board Group of companies “R-Pharm”, Co-Chairman on International Affairs of All-Russia Business Association “Delovaya Rossiya” (“Business Russia”) participated in the Forum events, such as meeting with Dmitry Medvedev, Prime Minister of the Russian Federation, with the business community, attended the plenary sessions and the panel discussions.

The participation of Group of Companies “R-Pharm” in the Forum resulted in signature of two separate development and commercialization agreements with R-Pharm. The first was for TD-1792, an investigational glycopeptide-cephalosporin heterodimer antibiotic for the treatment of resistant Gram-positive infections, which has completed a Phase 2 proof-of-concept study. The second was for telavancin, a lipoglycopeptide antibiotic approved in the United States. Under the R-Pharm agreements, Theravance granted R-Pharm exclusive development and commercialization rights for TD-1792 and telavancin in the Russian Federation, Ukraine, the other member countries of the Commonwealth of Independent States, and Georgia.

Mikhail Samsonov, Chief Medical Officer of R-Pharm together with Merck Company and Eli Lilly Company, the leaders of pharmaceutical industry, with the support of leading Russian health care experts, have raised important social issues, i.e. the development and implementation of innovative treatments as the necessary condition of effective struggle with the socially significant and life-threatening diseases that reflects the effective health care system in general, in terms of Round-table “Innovations in practical healthcare on 2nd of November.

The Forum united the government and business representatives for effective dialogue on different aspects of innovative country development. In particular, the question on the innovative health care industry development was raised during the Business Breakfast Meeting organized by the Association of International Pharmaceutical Manufacturers (AIPM), the Agency of Strategic Initiatives (ASI), the Association of Russian Pharmaceutical Manufacturers (ARPM), and All-Russia Business Association “Delovaya Rossiya” (“Business Russia”) supported by Group of Companies “R-Pharm”. Among the participants of Business Breakfast Meeting were Sergey Tsyb, Director of the Department for Chemical and Engineering Complex and Bioengineering Technologies of Ministry of Industry and Trade (MIT), Timophey Nizhegorodtsev, Head of Department for Social Area and Trading Control of Federal Anti-Monopoly Service of the Russian Federation, G. Steven Burrill, President of Burrill & Company, and the directors of the world’s leading pharmaceutical companies. The participants discussed the challenges of practical application of innovative medicines and forms of government and business cooperation aimed at the availability enhancement of high-efficient methods of treatement.